Futura Medical PLC Futura Medical AGM Results (5207Q)

TIDMFUM

RNS Number : 5207Q

Futura Medical PLC

28 June 2022

28 June 2022

Futura Medical plc

("Futura" or the "Company")

Futura Medical Announces Annual General Meeting Results

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology and currently focused on sexual health and pain, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.

The total number of votes received on each resolution were as follows:

 
                                     Voting For              Voting Against 
----------------------------------                                              ------------------------------------- 
                                     Number         %        Number      %       Total         % ISC    Votes 
                                      of votes(i)             of votes            Votes                  withheld(ii) 
------------  --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To accept 
                the Annual 
 Resolution     Report and 
  1             accounts             132,535,568    95.80%   5,769,918   4.20%   138,305,486   48.14%   70,831 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To appoint 
 Resolution     Jeff Needham 
  2             as a Director        138,246,246    99.98%   27,676      0.02%   138,273,922   48.13%   102,395 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To appoint 
 Resolution     Andrew Unitt 
  3             as a Director        138,250,441    99.98%   23,481      0.02%   138,273,922   48.13%   102,395 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To re-elect 
 Resolution     Ken James 
  4             as a Director        138,243,746    99.98%   30,676      0.02%   138,274,422   48.13%   101,895 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To re-appoint 
                Grant Thornton 
 Resolution     UK LLP as 
  5             Auditor              138,244,578    99.96%   49,908      0.04%   138,294,486   48.14%   81,831 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To authorise 
                the Directors 
                to determine 
                the remuneration 
 Resolution     of Grant Thornton 
  6             UK LLP               138,276,015    99.97%   40,471      0.03%   138,316,486   48.14%   59,831 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               To authorise 
                the directors 
                of the Company 
                to issue and 
                allot relevant 
                securities 
                (up to 1/3 
                of the existing 
                issued share 
                capital) pursuant 
                to section 
                551 of the 
 Resolution     Companies 
  7             Act 2006             138,239,449    99.95%   65,970      0.05%   138,305,419   48.14%   70,898 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               A Special 
                Resolution 
                empowering 
                the Directors 
                to disapply 
                the pre-emption 
                provision 
                of section 
                561 of the 
                Act in connection 
                with an offer 
                of equity 
                securities 
                by way of 
                a Rights Issue 
                or up to an 
                aggregate 
 Resolution     nominal value 
  8 (iii)       of GBP28,729.00      138,150,793    99.90%   135,129     0.10%   138,285,922   48.13%   90,395 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
               A Special 
                Resolution 
                empowering 
                the Directors 
                to disapply 
                the pre-emption 
                provision 
                of section 
                561 of the 
                Act in connection 
                with an offer 
                of equity 
                securities 
                to fund an 
                acquisition 
 Resolution     or a capital 
  9             transaction          138,170,921    99.92%   111,934     0.08%   138,282,855   48.13%   93,462 
              --------------------  -------------  -------  ----------  ------  ------------  -------  -------------- 
 

Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution

A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution

Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 24 June 2022 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 287,296,527 ordinary shares of 0.2p each. The Company does not hold any shares in treasury

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) technology. Each DermaSys(R) formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFESRFITFIF

(END) Dow Jones Newswires

June 28, 2022 10:58 ET (14:58 GMT)